WO1992015284A1 - Gas and oxygen carrying lipid vesicles - Google Patents
Gas and oxygen carrying lipid vesicles Download PDFInfo
- Publication number
- WO1992015284A1 WO1992015284A1 PCT/US1992/001584 US9201584W WO9215284A1 WO 1992015284 A1 WO1992015284 A1 WO 1992015284A1 US 9201584 W US9201584 W US 9201584W WO 9215284 A1 WO9215284 A1 WO 9215284A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- paucilamellar
- vesicles
- vesicle
- filled
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 128
- 239000007789 gas Substances 0.000 title claims description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims description 12
- 239000001301 oxygen Substances 0.000 title claims description 12
- 229910052760 oxygen Inorganic materials 0.000 title claims description 12
- 239000007788 liquid Substances 0.000 claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 28
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 26
- -1 polyoxyethylene Polymers 0.000 claims description 23
- 108010010803 Gelatin Proteins 0.000 claims description 12
- 239000000232 Lipid Bilayer Substances 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims description 12
- 229950011087 perflunafene Drugs 0.000 claims description 12
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 claims description 12
- 239000008273 gelatin Substances 0.000 claims description 11
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 239000002195 soluble material Substances 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 230000036571 hydration Effects 0.000 claims description 6
- 238000006703 hydration reaction Methods 0.000 claims description 6
- 229950008618 perfluamine Drugs 0.000 claims description 5
- JAJLKEVKNDUJBG-UHFFFAOYSA-N perfluorotripropylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F JAJLKEVKNDUJBG-UHFFFAOYSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 230000000887 hydrating effect Effects 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000004341 Octafluorocyclobutane Substances 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 229920000180 alkyd Polymers 0.000 claims description 3
- 150000005690 diesters Chemical class 0.000 claims description 3
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019407 octafluorocyclobutane Nutrition 0.000 claims description 3
- 229960004624 perflexane Drugs 0.000 claims description 3
- LOQGSOTUHASIHI-UHFFFAOYSA-N perfluoro-1,3-dimethylcyclohexane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(C(F)(F)F)C1(F)F LOQGSOTUHASIHI-UHFFFAOYSA-N 0.000 claims description 3
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 3
- 229940072056 alginate Drugs 0.000 claims 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 24
- 239000011800 void material Substances 0.000 abstract description 5
- 229920002545 silicone oil Polymers 0.000 abstract description 3
- 239000003921 oil Substances 0.000 description 28
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 6
- 229940086555 cyclomethicone Drugs 0.000 description 6
- 239000003973 paint Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000002577 cryoprotective agent Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000015096 spirit Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007332 vesicle formation Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- CBJZFQUYNWMEMC-UHFFFAOYSA-N 18-methyl-N-octadecylnonadecan-1-amine Chemical compound CC(CCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC)C CBJZFQUYNWMEMC-UHFFFAOYSA-N 0.000 description 1
- ZITBHNVGLSVXEF-UHFFFAOYSA-N 2-[2-(16-methylheptadecoxy)ethoxy]ethanol Chemical compound CC(C)CCCCCCCCCCCCCCCOCCOCCO ZITBHNVGLSVXEF-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019000 fluorine Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
- A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/20—After-treatment of capsule walls, e.g. hardening
- B01J13/203—Exchange of core-forming material by diffusion through the capsule wall
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
- C11D17/0017—Multi-phase liquid compositions
- C11D17/0021—Aqueous microemulsions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
- C11D17/0026—Structured liquid compositions, e.g. liquid crystalline phases or network containing non-Newtonian phase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Definitions
- a nonvolatile hydrophobic material such as a paraffin wax
- a nonvolatile hydrophobic material such as a paraffin wax
- vesicles have a monolayer of a surfactant surrounding the hydrophobic core, either from cannibalizing the wall material or by adding a separate, indifferent (or nonvesicle forming surfactant) in the manufacture of the vesicle.
- the surfactant stabilized wax droplets limit the collapse of this central core, forming tiny, solid particles and leading to relatively easy rehydration.
- the present invention relates to the use of moderately volatile liquids as an attempt to solve the problem.
- moderately volatile liquid means and implies a liquid that is less volatile than water but more volatile than the lipids which form the bilayer structure of the vesicles.
- These moderately volatile liquids have a vapor pressure such that they are able to leach out of the lipid vesicles when air dried, dried under a vacuum, or lyophilized, but they do so at a slower rate than the encapsulated aqueous solution. Accordingly, substantially all of the aqueous solution encapsulated in the vesicle, as well as the aqueous solution surrounding the vesicle, evaporates before the moderately volatile liquid and the moderately volatile liquid provides structure to the vesicle as the water is removed.
- perfluorocarbons are, primarily, alkanes or cycloalkanes having all of the hydrogens replaced with fluorines. Certain of these perfluorocarbons, primarily, perfluorodecalin and perfluorotripropylamine, have an additional advantage; they can function as oxygen carriers. Most perfluorocarbons have a density of about two, have a high air-and oxygen-carrying capacity, and are substantially unreactive with most materials.
- Encapsulation of oxygen-rich perfluorocarbons could have substantial value for use in cosmetics or in fermentation because of their high in vitro oxygenation capacity.
- these materials have promise for a substantial number of medical uses. For example, for these materials would be advantageous if used as an infusion after trauma, for infusion for radiotherapy, for wound perfusion, in angioplasty, or in radioimaging.
- an object of the invention is to provide a method of encapsulating perfluorocarbons and other moderately volatile liquids.
- Another object of the invention is to provide a method of forming gas-filled lipid vesicles.
- a further object of the invention is to provide a whitener which could be used in a variety of industrial applications.
- Paucilamellar lipid vesicles having a moderately volatile liquid encapsulated therein have 2-10 lipid bilayers surrounding the large, amorphous central cavity.
- the first step in manufacturing these vesicles is forming a lipid phase by blending the wall-forming lipid (which provides the structure to the vesicles) and any other lipid soluble materials which are to be incorporated into the walls.
- One lipid soluble material which is often used is a sterol such as cholesterol which assists in the thermotropic phase transition. If any oil distinct from the moderately volatile liquid is to be encapsulated into the central cavity, it can be added at this stage or "cold loaded" later.
- the vessels can then be "cold loaded” with a moderately volatile liquid using the techniques described in United States Patent Application Serial No. 598,120.
- any oil to be carried by the vesicles is loaded at this stage using the same procedure.
- the formed vesicles are mixed with the moderately volatile liquid under gentle to moderate shear conditions, thereby encapsulating the moderately volatile liquid in the central cavity and driving off some (or all) of the water from the core.
- “hot loading” of the vesicles with the moderately volatile liquid is preferred. This is accomplished by dispersing or premixing the moderately volatile liquid in the lipid phase before hydration. This allows the hydration and mixing steps to be carried out simultaneously. However, using the "hot loading” technique, special care must be taken to keep the lipid phase homogeneous during hydration.
- the paucilamellar lipid vesicles having the moderately volatile liquid encapsulated therein are to be used as is, they are merely separated from the reactants. However, if gas-filled, e.g., air-filled, paucilamellar lipid vesicles are being formed, the aqueous solution and the moderately volatile liquid must be removed. This is accomplished by evaporating both liquids, e.g., by air drying, vacuum drying, or lyophilization of the vesicles. Vacuum drying is preferred.
- the gas-filled paucilamellar lipid vesicles may be used as a whitener because of their refractive properties.
- Nonionic lipids e.g., nonionic surfactants
- these nonionic lipids are preferably polyethylene fatty acid esters, polyethylene fatty acid ethers, diethanola ides, long chain acyl hexosa ides, long chain acyl amino acid amides, long chain amino acid amines, polyoxyethylene sorbitan esters, polyoxy glycerol mono-and diesters, glycerol mono-and distearate, glycerol mono-and dioleate, glycerol mono-and dipalmitate, and mixtures thereof.
- the most preferred lipids have a melting temperature of about 40°C.
- nonionic lipids certain charged lipids such as sarcosinates (sarcosinamides), betaines, and monomeric and dimeric alkyds have been found to be useful.
- phospholipids such as phosphatidylcholine can be used.
- An additional structural support material may be added to further stabilize the vesicles.
- This additional material is preferably a water soluble polymerizable material that provides additional structural support to the vesicles upon polymerization.
- Preferred water soluble polymerizable materials are gelatins, acrylates, acrylamides, alginates, carboxymethylcellulose, and similar polymers.
- Paucilamellar lipid vesicles having aqueous or oil-filled central cavities can be manufactured using standard techniques such as those disclosed in United States Patent No. 4,911,928 or United States Patent No. 4,855,090, the disclosure of which is also incorporated herein by reference. These vesicles are then "cold loaded" with the moderately volatile liquid by mixing the preformed vesicles with the moderately volatile liquid, preferably under gentle to moderate shear conditions. A syringe technique such as is described in United States Patent Application Serial No. 598,120 is preferred. This technique provides a liquid shear which is approximately equal to a relative flow rate of about 5-50 m/s though a 1 mm radius orifice.
- the perfluorocarbons are the preferred moderately volatile liquids but other materials such as certain silicone oils or volatile mineral spirits can also be used.
- the primary requirements are unreactivity with the lipid wall structure, immiscibility between the moderately volatile liquid and the lipid and aqueous solutions (as well as any oil to be encapsulated) and the ability to be evaporated from the vesicle without damaging the vesicle at a rate slower than the water is evaporated.
- Evaporation of the aqueous solutions and moderately volatile liquid can be carried out by a variety of methods. However, high heat evaporation should not be used as the lipid structure itself will be melted if too much heat is applied, thereby degrading the vesicles and defeating the purpose of the procedure. Similarly, too high a vacuum cannot be used. While lyophilization is an effective method of removing the liquids, it may be unnecessarily expensive except for large bulk production.
- test solution was water (designated "O"), perfluorooctane (a perfluorocarbon) or cyclomethicone (a silicone oil).
- O water
- perfluorooctane a perfluorocarbon
- cyclomethicone a silicone oil
- This Example indicates that there clearly is a void formed in the moderately volatile liquid vesicles after drying. Further, it indicates that a material like a perfluorocarbon is preferred to a cyclomethicone because of the greater white (or refractile) intensity.
- Example 2 a similar test to that described in Example 1 was carried out except the lipid used to form the vesicle was polyoxyethylene-4 stearyl alcohol in lieu of the polyoxyethylene-9 glyceryl monostearate.
- the vesicles were prepared using 4 ml of the heated lipid solution and 16 ml of an aqueous solution, either with or without gelatin in the aqueous phase. Again, the lipid phase was heated to approximately 70°C, the aqueous phase was heated to approximately 65°C, and the phases were blended using the syringe method described in Example 1.
- the first three samples (A-C) act as controls for the other samples.
- the solution was merely hazy if no moderately volatile liquid was used.
- heterogenous large vesicles had been apparent. These materials did not rehydrate into vesicles.
- Sample D also looked hazy under the oil but was somewhat more opaque than the control samples. Upon rehydration, vesicles reformed, showing that the bilayer structure still existed. Similar results were expected from samples F and H but no observation was made upon hydration.
- Sample E containing encapsulated perfluorooctane, showed results similar to those described in Example 1.
- This sample when viewed under oil, was white and opaque, showing a network of vesicles. Upon rehydrating, detached vesicles were abundant. Similarly, sample G was also opaque but the vesicles seemed slightly distorted. Upon rehydration, the vesicles were more tightly held than those of sample E, e.g., they did not flow as much. The rehydrated vesicles for sample G appeared to be in the form of sheets of defined vesicles. Sample I gave similar results to sample G.
- This Example establishes that the described procedure for vesicle manufacture having a moderately volatile liquid will form vesicles with a central void upon dehydration and that vesicles can be formed upon rehydration.
- the vesicles were made by blending 4 ml of polyoxyethylene-9 glyceryl monostearate with 16 ml of deionized water using the syringe technique of Example 1. After separation of the vesicles, and cooling to room temperature, 10 ml of the formed vesicles were blended with 2 ml of a mixture of 0.1% oil red 0 in mineral oil (Drakeol 19). The dye-containing oil and vesicles were syringed by the procedure of Example 1 for approximately two minutes, providing encapsulation of the oil. About 12 ml of the oil-filled vesicles were then blended with 2 ml of perfluorodecalin using the syringe technique of Example 1. The sample was observed under a light microscope before and after the addition of the perfluorodecalin. After observation, the vesicles were centrifuged for fifteen minutes at 3500 rpm. No separation of dye or perfluorodecalin was observed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4507835A JPH06507830A (en) | 1991-03-01 | 1992-02-26 | Lipid vesicles for gas and oxygen transport |
AU15388/92A AU660970B2 (en) | 1991-03-01 | 1992-02-26 | Gas and oxygen carrying lipid vesicles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/662,850 US5219538A (en) | 1987-03-13 | 1991-03-01 | Gas and oxygen carrying lipid vesicles |
US662,850 | 1991-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992015284A1 true WO1992015284A1 (en) | 1992-09-17 |
Family
ID=24659489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/001584 WO1992015284A1 (en) | 1991-03-01 | 1992-02-26 | Gas and oxygen carrying lipid vesicles |
Country Status (6)
Country | Link |
---|---|
US (1) | US5219538A (en) |
EP (1) | EP0573592A4 (en) |
JP (1) | JPH06507830A (en) |
AU (1) | AU660970B2 (en) |
CA (1) | CA2106405A1 (en) |
WO (1) | WO1992015284A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012145A2 (en) * | 1992-12-02 | 1994-06-09 | Unilever Plc | Cosmetic composition |
WO1994016739A1 (en) * | 1993-01-25 | 1994-08-04 | Sonus Pharmaceuticals, Inc. | Phase shift colloids as ultrasound contrast agents |
US5393524A (en) * | 1991-09-17 | 1995-02-28 | Sonus Pharmaceuticals Inc. | Methods for selecting and using gases as ultrasound contrast media |
US5536489A (en) * | 1993-06-04 | 1996-07-16 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
US5558094A (en) * | 1991-09-17 | 1996-09-24 | Sonus Pharmaceuticals, Inc. | Methods for using persistent gases as ultrasound contrast media |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US5558854A (en) * | 1991-09-17 | 1996-09-24 | Sonus Pharmaceuticals | Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas |
JPH09506098A (en) * | 1993-11-30 | 1997-06-17 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | Gas microspheres for topical and subcutaneous application |
EP0788348A1 (en) * | 1994-09-16 | 1997-08-13 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
EP0802788A1 (en) * | 1993-06-11 | 1997-10-29 | UNGER, Evan C | Novel therapeutic delivery systems |
EP1015039A1 (en) * | 1997-06-18 | 2000-07-05 | Imarx Pharmaceutical Corp. | Oxygen delivery agents and uses for the same |
US6132699A (en) * | 1996-03-05 | 2000-10-17 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
EP1252885A2 (en) * | 1993-06-11 | 2002-10-30 | Imarx Pharmaceutical Corp. | Methods of preparing gas and gaseous precursor-filled microspheres |
US6569404B1 (en) | 1993-01-25 | 2003-05-27 | Amersham Health A/S | Phase shift colloids as ultrasound contrast agents |
WO2003049706A2 (en) * | 2001-11-09 | 2003-06-19 | Or-Le-Or Ltd. | Wrinkle cream comprising hydrophillic and hydrophobic particles |
US9545457B2 (en) | 1998-01-14 | 2017-01-17 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US10022460B2 (en) | 2014-12-31 | 2018-07-17 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
CN110639032A (en) * | 2019-10-31 | 2020-01-03 | 南京景瑞康分子医药科技有限公司 | High-frequency ultrasonic contrast agent and preparation method thereof |
US10588988B2 (en) | 2016-05-04 | 2020-03-17 | Lantheus Medical Imaging, Inc. | Methods and devices for preparation of ultrasound contrast agents |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5656211A (en) | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5205290A (en) * | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
DE4221256C2 (en) * | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenic composition for topical use |
DE4221268C2 (en) * | 1992-06-26 | 1997-06-12 | Lancaster Group Ag | Use of a dermatological to support the oxygen transport in the skin |
US5641509A (en) * | 1992-06-26 | 1997-06-24 | Lancaster Group Ag | Preparation for topical use |
US5643601A (en) * | 1992-06-26 | 1997-07-01 | Lancaster Group Ag | Phospholipid-and fluorocarbon-containing cosmetic |
US5736121A (en) | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
CA2252617A1 (en) | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
DK1323434T3 (en) | 1996-09-11 | 2007-11-12 | Bristol Myers Squibb Medical I | Method for diagnostic imaging of kidney regions using a contrast agent and a vasodilator |
FR2757871B1 (en) * | 1996-12-27 | 1999-03-26 | Aerospatiale | WATERPROOFING COMPOSITION COMPRISING A HYDROPHOBIC AGENT AND A SOLVENT, APPLICATION FOR THE REMOVAL OF SURFACE WATER IN PARTICULAR FROM WINDSCREENS OF VEHICLES OR AIRCRAFT |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6039960A (en) | 1997-05-28 | 2000-03-21 | E-L Management Corp. | Water containing wax-based product |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
TW476788B (en) | 1998-04-08 | 2002-02-21 | Kimberly Clark Co | A cleanser and the making process thereof |
US6599441B1 (en) * | 2000-07-18 | 2003-07-29 | Emerald Biostructures, Inc. | Crystallization solutions |
US20040087564A1 (en) * | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
AU2005248294A1 (en) | 2004-04-07 | 2005-12-08 | The University Of Georgia Research Foundation, Inc. | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
US8034796B2 (en) * | 2004-04-07 | 2011-10-11 | The University Of Georgia Research Foundation, Inc. | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
WO2006071659A1 (en) * | 2004-12-29 | 2006-07-06 | Trustees Of Boston University | Delivery of h2 antagonists |
DK2023896T3 (en) * | 2006-05-19 | 2016-10-03 | Viroblock Sa | A composition for the inactivation of enveloped viruses |
EP2200652B1 (en) | 2007-09-27 | 2018-03-21 | Children's Medical Center Corporation | Microbubbles and methods for oxygen delivery |
US10251839B2 (en) * | 2008-01-22 | 2019-04-09 | Igi Laboratories, Inc. | Lipid vesicles derived from olive oil fatty acids |
WO2012065060A2 (en) * | 2010-11-12 | 2012-05-18 | Children's Medical Center Corporation | Gas-filled microbubbles and systems for gas delivery |
US10357450B2 (en) | 2012-04-06 | 2019-07-23 | Children's Medical Center Corporation | Process for forming microbubbles with high oxygen content and uses thereof |
US10577554B2 (en) | 2013-03-15 | 2020-03-03 | Children's Medical Center Corporation | Gas-filled stabilized particles and methods of use |
CN104353088A (en) * | 2014-09-30 | 2015-02-18 | 东南大学 | Preparation method of lipid bubbles |
WO2016164406A1 (en) * | 2015-04-06 | 2016-10-13 | The Regents Of The University Of Colorado, A Body Corporate | Intraocular oxygen delivery and absorption devices and methods |
WO2018160752A1 (en) | 2017-02-28 | 2018-09-07 | Children's Medical Center Corporation | Stimuli-responsive particles encapsulating a gas and methods of use |
CN108888767B (en) * | 2018-08-10 | 2021-05-25 | 中国科学院宁波材料技术与工程研究所 | Nano composite material, preparation method and application thereof |
CN116917029A (en) * | 2021-03-01 | 2023-10-20 | 国立大学法人东京大学 | Microparticles and microparticle dispersions |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4448765A (en) * | 1978-07-03 | 1984-05-15 | National Research Development Corporation | Liposomes and their use in treating human or other mammalian patients |
US4536324A (en) * | 1982-07-19 | 1985-08-20 | Lion Corporation | Nonionic surfactant type vesicle dispersion |
US4622219A (en) * | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
US4743449A (en) * | 1983-09-12 | 1988-05-10 | Fujisawa Pharmaceutical Co., Ltd. | Drug-containing lipid vesicle preparation and method for preparing them |
US4776991A (en) * | 1986-08-29 | 1988-10-11 | The United States Of America As Represented By The Secretary Of The Navy | Scaled-up production of liposome-encapsulated hemoglobin |
US4830857A (en) * | 1984-10-24 | 1989-05-16 | L'oreal | Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing these compositions |
US5061484A (en) * | 1988-03-11 | 1991-10-29 | Alpha Therapeutic Corporation | Perfluorochemical emulsion with stabilized vesicles |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2980941A (en) * | 1958-12-08 | 1961-04-25 | Ncr Co | Cleaning sheet |
CA795288A (en) * | 1966-11-12 | 1968-09-24 | Chapuis Jacques | Encapsulated synthetic liquid detergent and process for preparing the same |
US4212758A (en) * | 1978-10-20 | 1980-07-15 | Belkevich Petr I | Cleansing agents containing oleic acid, isopropanol and ethylacetate |
US4297374A (en) * | 1979-10-11 | 1981-10-27 | Wess Beatrice M | Skin moisturizing and cleansing cream |
US4452818A (en) * | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
US4742050B1 (en) * | 1982-08-17 | 1994-06-28 | Alpha Therapeutic Corp | Sensitization of hypoxic tumor cells and control of growth thereof |
US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
US4814270A (en) * | 1984-09-13 | 1989-03-21 | Becton Dickinson And Company | Production of loaded vesicles |
US5077036A (en) * | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
US4865836A (en) * | 1986-01-14 | 1989-09-12 | Fluoromed Pharmaceutical, Inc. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
US5080885A (en) * | 1986-01-14 | 1992-01-14 | Alliance Pharmaceutical Corp. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
US4722904A (en) * | 1986-12-18 | 1988-02-02 | Fisher Scientific Company | Thermodynamically-stable aqueous perfluorocarbon microemulsion useful as blood gas control or calibrator |
US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4942038A (en) * | 1987-03-13 | 1990-07-17 | Micro Vesicular Systems, Inc. | Encapsulated humectant |
US5104736A (en) * | 1988-03-03 | 1992-04-14 | Micro-Pak, Inc. | Reinforced paucilamellar lipid vesicles |
US5160669A (en) * | 1988-03-03 | 1992-11-03 | Micro Vesicular Systems, Inc. | Method of making oil filled paucilamellar lipid vesicles |
WO1989008459A1 (en) * | 1988-03-11 | 1989-09-21 | Alpha Therapeutic Corporation | Perfluorochemical emulsion with stabilized vesicles |
US4993415A (en) * | 1988-08-19 | 1991-02-19 | Alliance Pharmaceutical Corp. | Magnetic resonance imaging with perfluorocarbon hydrides |
EP0375610A3 (en) * | 1988-12-19 | 1992-01-02 | Ciba-Geigy Ag | Perfluoroalkylthioglycosides |
AU5666090A (en) * | 1989-05-25 | 1990-12-18 | Technology Unlimited Incorporated | Insect repellant |
EP0478686B1 (en) * | 1989-06-22 | 1993-08-11 | Applications Et Transferts De Technologies Avancees Atta | Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties |
WO1991000110A1 (en) * | 1989-07-05 | 1991-01-10 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions having saturated phospholipid emulsifiers |
FR2658721B1 (en) * | 1990-02-23 | 1992-06-19 | Oreal | METHOD FOR MANUFACTURING A COSMETIC COMPOSITION FOR APPLICATION TO HAIR, COMPOSITION OBTAINED BY THIS PROCESS AND METHOD FOR COSMETIC TREATMENT USING THE SAME. |
US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
-
1991
- 1991-03-01 US US07/662,850 patent/US5219538A/en not_active Expired - Lifetime
-
1992
- 1992-02-26 JP JP4507835A patent/JPH06507830A/en active Pending
- 1992-02-26 AU AU15388/92A patent/AU660970B2/en not_active Ceased
- 1992-02-26 EP EP19920908181 patent/EP0573592A4/en not_active Withdrawn
- 1992-02-26 WO PCT/US1992/001584 patent/WO1992015284A1/en not_active Application Discontinuation
- 1992-02-26 CA CA002106405A patent/CA2106405A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4448765A (en) * | 1978-07-03 | 1984-05-15 | National Research Development Corporation | Liposomes and their use in treating human or other mammalian patients |
US4536324A (en) * | 1982-07-19 | 1985-08-20 | Lion Corporation | Nonionic surfactant type vesicle dispersion |
US4622219A (en) * | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
US4743449A (en) * | 1983-09-12 | 1988-05-10 | Fujisawa Pharmaceutical Co., Ltd. | Drug-containing lipid vesicle preparation and method for preparing them |
US4830857A (en) * | 1984-10-24 | 1989-05-16 | L'oreal | Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing these compositions |
US4776991A (en) * | 1986-08-29 | 1988-10-11 | The United States Of America As Represented By The Secretary Of The Navy | Scaled-up production of liposome-encapsulated hemoglobin |
US5061484A (en) * | 1988-03-11 | 1991-10-29 | Alpha Therapeutic Corporation | Perfluorochemical emulsion with stabilized vesicles |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
Non-Patent Citations (1)
Title |
---|
See also references of EP0573592A4 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5558854A (en) * | 1991-09-17 | 1996-09-24 | Sonus Pharmaceuticals | Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas |
US5393524A (en) * | 1991-09-17 | 1995-02-28 | Sonus Pharmaceuticals Inc. | Methods for selecting and using gases as ultrasound contrast media |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
US5573751A (en) * | 1991-09-17 | 1996-11-12 | Sonus Pharmaceuticals, Inc. | Persistent gaseous bubbles as ultrasound contrast media |
US5558094A (en) * | 1991-09-17 | 1996-09-24 | Sonus Pharmaceuticals, Inc. | Methods for using persistent gases as ultrasound contrast media |
WO1994012145A3 (en) * | 1992-12-02 | 1994-07-21 | Unilever Plc | Cosmetic composition |
WO1994012145A2 (en) * | 1992-12-02 | 1994-06-09 | Unilever Plc | Cosmetic composition |
US5707606A (en) * | 1993-01-25 | 1998-01-13 | Sonus Pharmaceuticals, Inc. | Phase shift colloids as ultrasound contrast agents |
KR100332166B1 (en) * | 1993-01-25 | 2002-11-16 | 아머샴 헬쓰 에이에스 | Phase-modified colloidal acid solution as an ultrasonic contrast agent |
US5558853A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
CN1068230C (en) * | 1993-01-25 | 2001-07-11 | 索纳斯药品有限公司 | Phase shift colloids as ultrasound contrast agents |
EP1038535A3 (en) * | 1993-01-25 | 2003-10-29 | Amersham Health AS | Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents |
AU680652B2 (en) * | 1993-01-25 | 1997-08-07 | Ge Healthcare As | Phase shift colloids as ultrasound contrast agents |
US6569404B1 (en) | 1993-01-25 | 2003-05-27 | Amersham Health A/S | Phase shift colloids as ultrasound contrast agents |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
EP1038535A2 (en) * | 1993-01-25 | 2000-09-27 | Sonus Pharmaceuticals, Inc. | Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents |
US5707607A (en) * | 1993-01-25 | 1998-01-13 | Sonus Pharmaceuticals, Inc. | Phase shift colloids as ultrasound contrast agents |
WO1994016739A1 (en) * | 1993-01-25 | 1994-08-04 | Sonus Pharmaceuticals, Inc. | Phase shift colloids as ultrasound contrast agents |
US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
US5536489A (en) * | 1993-06-04 | 1996-07-16 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
US6030603A (en) * | 1993-06-04 | 2000-02-29 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
EP1252885A2 (en) * | 1993-06-11 | 2002-10-30 | Imarx Pharmaceutical Corp. | Methods of preparing gas and gaseous precursor-filled microspheres |
EP0802788A4 (en) * | 1993-06-11 | 1998-09-09 | Evan C Unger | Novel therapeutic delivery systems |
EP0802788A1 (en) * | 1993-06-11 | 1997-10-29 | UNGER, Evan C | Novel therapeutic delivery systems |
EP1252885A3 (en) * | 1993-06-11 | 2003-04-16 | Imarx Pharmaceutical Corp. | Methods of preparing gas and gaseous precursor-filled microspheres |
JPH09506098A (en) * | 1993-11-30 | 1997-06-17 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | Gas microspheres for topical and subcutaneous application |
EP0788348A4 (en) * | 1994-09-16 | 1998-04-01 | Imarx Pharmaceutical Corp | Container with multi-phase composition for use in diagnostic and therapeutic applications |
EP0788348A1 (en) * | 1994-09-16 | 1997-08-13 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6132699A (en) * | 1996-03-05 | 2000-10-17 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
EP1015039A4 (en) * | 1997-06-18 | 2002-09-11 | Imarx Pharmaceutical Corp | Oxygen delivery agents and uses for the same |
EP1015039A1 (en) * | 1997-06-18 | 2000-07-05 | Imarx Pharmaceutical Corp. | Oxygen delivery agents and uses for the same |
US9545457B2 (en) | 1998-01-14 | 2017-01-17 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
WO2003049706A2 (en) * | 2001-11-09 | 2003-06-19 | Or-Le-Or Ltd. | Wrinkle cream comprising hydrophillic and hydrophobic particles |
US6808715B2 (en) | 2001-11-09 | 2004-10-26 | Or-Le-Or Ltd. | Wrinkle cream |
US7294349B2 (en) | 2001-11-09 | 2007-11-13 | Or Le Or Ltd. | Wrinkle cream |
WO2003049706A3 (en) * | 2001-11-09 | 2004-03-11 | Or Le Or Ltd | Wrinkle cream comprising hydrophillic and hydrophobic particles |
US11395856B2 (en) | 2014-12-31 | 2022-07-26 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
US10583207B2 (en) | 2014-12-31 | 2020-03-10 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
US10022460B2 (en) | 2014-12-31 | 2018-07-17 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
US10588988B2 (en) | 2016-05-04 | 2020-03-17 | Lantheus Medical Imaging, Inc. | Methods and devices for preparation of ultrasound contrast agents |
US12097270B2 (en) | 2016-05-04 | 2024-09-24 | Lantheus Medical Imaging, Inc. | Methods and devices for preparation of ultrasound contrast agents |
US11344636B2 (en) | 2016-07-06 | 2022-05-31 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US10220104B2 (en) | 2016-07-06 | 2019-03-05 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US9913919B2 (en) | 2016-07-06 | 2018-03-13 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11266750B2 (en) | 2016-07-06 | 2022-03-08 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11266749B2 (en) | 2016-07-06 | 2022-03-08 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11529431B2 (en) | 2016-07-06 | 2022-12-20 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11857646B2 (en) | 2016-07-06 | 2024-01-02 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11925695B2 (en) | 2016-07-06 | 2024-03-12 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US10583208B2 (en) | 2016-07-06 | 2020-03-10 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
CN110639032A (en) * | 2019-10-31 | 2020-01-03 | 南京景瑞康分子医药科技有限公司 | High-frequency ultrasonic contrast agent and preparation method thereof |
CN110639032B (en) * | 2019-10-31 | 2022-09-30 | 南京景瑞康分子医药科技有限公司 | High-frequency ultrasonic contrast agent and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0573592A4 (en) | 1994-03-18 |
AU1538892A (en) | 1992-10-06 |
AU660970B2 (en) | 1995-07-13 |
CA2106405A1 (en) | 1992-09-02 |
JPH06507830A (en) | 1994-09-08 |
EP0573592A1 (en) | 1993-12-15 |
US5219538A (en) | 1993-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU660970B2 (en) | Gas and oxygen carrying lipid vesicles | |
Farmer et al. | [18] Liposome-encapsulated hemoglobin as an artificial oxygen-carrying system | |
US5089181A (en) | Method of dehydrating vesicle preparations for long term storage | |
US5104736A (en) | Reinforced paucilamellar lipid vesicles | |
CA2133421C (en) | Process for the preparation of microcapsules or liposomes of controlled sizes | |
Weiner et al. | Liposomes as a drug delivery system | |
US5874111A (en) | Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles | |
US4606940A (en) | Small particle formation and encapsulation | |
US5985354A (en) | Preparation of multiwall polymeric microcapsules from hydrophilic polymers | |
Rathod et al. | Design and evaluation of liposomal formulation of pilocarpine nitrate | |
EP1660227A1 (en) | Method for improving the properties of amphiphile particles | |
WO2002049617A2 (en) | Self forming, thermodynamically stable liposomes and their applications | |
Kikuchi et al. | A polyol dilution method for mass production of liposomes | |
Rao | Preparation of liposomes on the industrial scale: Problems and perspectives | |
US5173219A (en) | Uniform spherical multilamellar liposomes of defined and adjustable size distribution | |
Elorza et al. | Comparison of particle size and encapsulation parameters of three liposomal preparations | |
AU612631B2 (en) | Dehydrating vesicule preparations for long-term storage | |
Crommelin et al. | Liposomes as carriers for drugs and antigens: approaches to preserve their long term stability | |
US6537575B1 (en) | Synthetic biological membrane with self organizing properties | |
WO2007063156A1 (en) | Liposome preparation method | |
US20070122469A1 (en) | Method for producing a vesicle dispersion | |
Zheng et al. | Liposome microencapsulations without using any organic solvent | |
US4743583A (en) | Sustained release protein compositions and method for making | |
AU753677B2 (en) | Improved method for avoiding the degradation of an active principle | |
Kaneko et al. | Formation of homogeneous liposomes with high trapping efficiency by the surface chemical method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CS JP KR NO PL RU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2106405 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992908181 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992908181 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992908181 Country of ref document: EP |